A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration.

The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax ...

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The biochemist’s company, Vega Oncotargets, has toned down its message after the false expectations generated by the ...

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to the abdomen in adult patients with locally advanced pancreatic cancer, ...

Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment ...

Researchers say an immunotherapy they used represents a significant step forward and could lead to new treatment options, even for other forms of cancer ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

FDA clears 1st treatment for pancreatic cancer in 30 years, approving Optune Pax to improve survival with chemotherapy.

The scientists found that KLF5 had the greatest effect specifically promoting the growth and invasion of metastatic cells, ...

The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...